Malcolm:
Photography <a href=" http://www.palmecenter.se/generic-for-celebrex-prices.pdf ">what is the medication celebrex 200 mg for</a> Last fall Novartis tapped secukinumab as one of 14 leading drug hopefuls in the late-stage pipeline, an impressive lineup for a pharma giant that spends an industry-leading $9.5 billion a year on R&D. In addition to psoriasis, Novartis plans to release more late-stage results for arthritic conditions next year. And the pharma giant told investors two years ago that secukinumab was a blockbuster contender, with its first regulatory filing slated for this year. 聽
    Malcolm写于2015/5/28 1:53:54